ERBB2 and neoplasm: A monoclonal antibody used to suppress the action of HER2 protein is trastuzumab, which blocks the action of HER2+ by inducing cell cycle arrest, interfering with intracellular signals and inhibiting tumour cell proliferation and migration [47].